MY155633A - Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy - Google Patents

Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Info

Publication number
MY155633A
MY155633A MYPI2010000753A MYPI20100753A MY155633A MY 155633 A MY155633 A MY 155633A MY PI2010000753 A MYPI2010000753 A MY PI2010000753A MY PI20100753 A MYPI20100753 A MY PI20100753A MY 155633 A MY155633 A MY 155633A
Authority
MY
Malaysia
Prior art keywords
treatment
inhibitors
huntington
disease
mipo
Prior art date
Application number
MYPI2010000753A
Other languages
English (en)
Inventor
Eriksson Håkan
Poewe Werner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY155633A publication Critical patent/MY155633A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI2010000753A 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy MY155633A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
MY155633A true MY155633A (en) 2015-11-13

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010000753A MY155633A (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
MX2014011752A (es) * 2012-03-29 2015-04-17 Basf Se Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
MX2019015578A (es) * 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
US11246870B2 (en) * 2017-07-17 2022-02-15 Astrazenca Ab MPO inhibitors for use in medicine
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
CA3173805A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
US20240166642A1 (en) 2022-08-18 2024-05-23 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
EP4624473A4 (en) * 2022-12-09 2026-03-25 Shenzhen Salubris Pharm Co Ltd DERIVATIVE OF PYRROLO[3,2-D]PYRIMIDIN-4-ONE, ITS PREPARATION PROCESS AND ITS MEDICAL USE
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
BR0306919A (pt) * 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
US20090124640A1 (en) * 2006-06-05 2009-05-14 Astrazeneca Ab Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
EP2200616A1 (en) 2010-06-30
HRP20130139T1 (hr) 2013-03-31
ME01510B (me) 2014-04-20
IL240130A0 (en) 2015-09-24
AU2008289653B2 (en) 2012-06-28
CA2698205C (en) 2016-06-21
CN103638029A (zh) 2014-03-19
CY1113714T1 (el) 2016-06-22
US20200405724A1 (en) 2020-12-31
KR20100055434A (ko) 2010-05-26
US20140221400A1 (en) 2014-08-07
CN105687199A (zh) 2016-06-22
BRPI0815681A2 (pt) 2015-02-18
SI2200616T1 (sl) 2013-03-29
PL2200616T3 (pl) 2013-04-30
MX2010001983A (es) 2010-03-10
WO2009025618A1 (en) 2009-02-26
AU2008289653A1 (en) 2009-02-26
CN113633641A (zh) 2021-11-12
PT2200616E (pt) 2013-02-27
HK1145141A1 (en) 2011-04-08
US10772890B2 (en) 2020-09-15
KR101588464B1 (ko) 2016-01-25
EA201000202A1 (ru) 2010-10-29
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
US20090054468A1 (en) 2009-02-26
US20130059870A1 (en) 2013-03-07
PH12014501180A1 (en) 2015-08-24
EA017510B1 (ru) 2013-01-30
US20190099423A1 (en) 2019-04-04
CN101873857A (zh) 2010-10-27
JP2013151547A (ja) 2013-08-08
US20110207755A1 (en) 2011-08-25
CA2698205A1 (en) 2009-02-26
ES2399846T3 (es) 2013-04-03
JP5247804B2 (ja) 2013-07-24
ZA201000848B (en) 2012-07-25
EP2200616A4 (en) 2010-08-25
DK2200616T3 (da) 2013-03-04
NZ584135A (en) 2012-04-27
RS52665B (sr) 2013-06-28
EP2200616B1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL193356A0 (en) Use of rasagiline for the treatment of multiple system atrophy
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
CA2865011C (en) Methods and compositions for treating huntington's disease
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
SG134180A1 (en) Composition for treating or preventing hot flashes and use thereof
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren
UA94737C2 (ru) Соединения на основе имидазола, композиция, которая их содержит, и их применение
UA102523C2 (ru) Применение ингибиторов миелопероксидазы для лечения множественной системной атрофии
AU2015201137B2 (en) Compositions and method for tissue preservation
HK1154911A (en) Methods and compositions for the treatment of huntington's disease
UA42783U (ru) Способ лечения дисбактериоза